ClinicalTrials.gg
CompletedNCT04729101Updated Mar 31, 2023Results posted

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

A Phase 1 interventional study of Vonoprazan and Lansoprazole in Healthy Participants, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-31.

Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of vonoprazan (20 mg) and lansoprazole (30 mg) following single (Day 1) and multiple doses (Day 7).

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

02

Conditions studied

  • Healthy Participants

Keywords

  • Vonoprazan
  • Lansoprazole
03

In context

Lead sponsor

Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must fulfill all the following inclusion criteria to be eligible for participation in the study:

    1. Healthy, adult, male or female 18 - 55 years of age, inclusive, at screening.
    2. Continuous nonsmoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on participant self-reporting.
    3. (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2 at screening.
    4. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs, or (ECGs), as deemed by the principal investigator (PI) or designee.
    5. Alkaline phosphatase (ALP), (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) \< upper limits of the clinical laboratory reference range (one recheck is permissible).
    6. A female of is either sexually inactive (abstinent as a life style) for 28 days prior to the first dosing and throughout the study or is using one of the following acceptable methods:

      • hormonal oral contraceptives, vaginal ring, transdermal patch, or hormone releasing intrauterine device for at least 3 months prior to the first dosing and with either a physical (e.g., condom, diaphragm, or other) or a chemical (e.g., spermicide) barrier method from the time of screening and throughout the study.
      • Depot/implantable hormone (e.g., Depo-Provera®, Implanon®) for at least 3 months prior to the first dosing and throughout the study.

      In addition, female participants of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method for at least 28 days after the last dose.

    7. A female of non-childbearing potential has undergone one of the following sterilization procedures at least 6 months prior to the first dosing:

      • hysteroscopic sterilization;
      • bilateral tubal ligation or bilateral salpingectomy;
      • hysterectomy;
      • bilateral oophorectomy;

      or be with amenorrhea for at least 1 year prior to the first dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status.

    8. A non-vasectomized, male participant must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomized less than 4 months prior to study first dosing must follow the same restrictions as a non-vasectomized male).
    9. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing.
    10. Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  • Participants must not be enrolled in the study if they meet any of the following criteria:

    1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
    2. History or presence of medical or psychiatric condition or disease in the opinion of the principal investigator (PI) or designee.
    3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
    4. History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
    5. History or presence of or idiosyncratic reaction to the study drug(s), its , related compounds, or lidocaine.
    6. Clinically significant gastrointestinal (GI) disorder (e.g., gastric ulcer (GU), Gastroesophageal reflux disease (GERD), impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, bowel obstruction, bariatric surgery, cholecystitis [including history of cholecystectomy], and/or appendectomy).
    7. Positive result for H. pylori breath test at screening.
    8. Had diarrhea or vomiting within 48 hours prior to check-in.
    9. Has nasal abnormalities that could affect pH probe insertion.
    10. Cannot tolerate placement of the pH probe.
    11. Female participants with a positive pregnancy test at screening or check-in or who are lactating.
    12. Positive urine drug or alcohol results at screening or check-in.
    13. Positive results at screening for (HIV), surface antigen (HBsAg), or virus (HCV).
    14. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
    15. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
    16. Fridericia's correction to the (QTcF) interval is >460 msec (males) or >470 msec (females) or has (ECG) findings deemed abnormal with clinical significance by the PI or designee at screening.
    17. Estimated \<80 mL/min at screening.
    18. The participant has serum creatinine >1.22 mg/dL at screening or check-in.
    19. Unable to refrain from or anticipates the use of:

      • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing and throughout the study. Medication listed as part of acceptable methods will be allowed. After randomization, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee. Topical lidocaine may be administered for pH probe insertion. Hormone replacement therapy will also be allowed.
      • Any drugs known to be significant inducers of /5, CYP1A2, and/or CYP2C19 for 28 days prior to the first dosing and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of PK / PD interaction with study drug.
    20. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study.
    21. Donation of blood or significant blood loss within 56 days prior to the first dosing.
    22. Plasma donation within 7 days prior to the first dosing.
    23. Participation in another clinical study within 30 days prior to the first dosing. The 30 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Treatment A (vonoprazan)

    Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2. Vonoprazan will be administered via 20 mg oral tablet once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days.

    Drug: Vonoprazan

  • Active comparator
    Treatment B (lansoprazole)

    Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2. Lansoprazole will be administered via 30 mg oral capsule once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days.

    Drug: Lansoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Gastric pH >4 Holding Time Ratio (HTR): Percentage of Time Gastric pH Was Above 4 Over a 24-hour Monitoring Period Following Study Drug Administration

    Calculated as: Time pH \>4\*100/total actual monitoring period time. Gastric pH was measured continuously over a 24-hour period on Days 1 and 7 of Periods 1 and 2, using a pH and pressure sensitive probe and ambulatory pH recording system. A pH recording was taken every second.

    Time frame: Day 1 and Day 7 of each treatment period

  2. Mean Gastric pH Over a 24-hour Monitoring Period Following Study Drug Administration (pH0-24)

    The average gastric pH was a measure of the immediate effect on gastric pH and the duration of effect on gastric pH. Gastric pH was measured continuously over a 24-hour period on Days 1 and 7 of Periods 1 and 2, using a pH and pressure sensitive probe and ambulatory pH recording system. A pH recording was taken every second. The pH scale ranges from 0 to 14 with values below 7 being more acidic and values above 7 being more basic. Normal gastric pH is between 1.5 and 3.5.

    Time frame: Day 1 and Day 7 of each treatment period

  3. Area Under the Concentration-Time Curve From Time 0 to the 24-Hour Time Point (AUC0-24)

    Calculated using the Linear Trapezoidal with Linear Interpolation Method. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

    Time frame: Day 1: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose

  4. Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)

    Calculated as the area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) + (Clast/Kel) where Clast is the last observed/measured concentration and Kel is the apparent first-order terminal elimination rate constant. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

    Time frame: Day 1: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose

  5. Maximum Observed Plasma Concentration (Cmax)

    Cmax was taken directly from bioanalytical data. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

    Time frame: Day 1: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose

  6. Time to Reach Cmax (Tmax)

    Taken from the clinical database as the difference in the time of administration and the time of the blood draw which was associated with the Cmax. If the maximum value occurred at more than one time point, Tmax was defined as the first time point with this value. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

    Time frame: Day 1: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose

  7. Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) at Steady State (ss)

    Calculated using the Linear Trapezoidal with Linear Interpolation Method. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

    Time frame: Day 7: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose

  8. Cmax at Steady State (Cmax,ss)

    Cmax,ss was taken directly from bioanalytical data. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

    Time frame: Day 7: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose

  9. Tmax at Steady State (Tmax,ss)

    Taken from the clinical database as the difference in the time of administration and the time of the blood draw which was associated with the Cmax,ss. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

    Time frame: Day 7: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose

07

Results

Posted Mar 31, 2023

Participant flow

A total of 44 participants were enrolled between January 2021 and June 2021 at a single site in the United States.

Participant flow — Overall Study
MilestoneFirst Vonoprazan, Then Lansoprazole (Treatment Sequence AB)First Lansoprazole, Then Vonoprazan (Treatment Sequence BA)
Started2321
Received treatment2321
Completed2021
Not completed30
Withdrew: Adverse event10
Withdrew: Physician decision10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryGastric pH >4 Holding Time Ratio (HTR): Percentage of Time Gastric pH Was Above 4 Over a 24-hour Monitoring Period Following Study Drug Administration

Calculated as: Time pH \>4\*100/total actual monitoring period time. Gastric pH was measured continuously over a 24-hour period on Days 1 and 7 of Periods 1 and 2, using a pH and pressure sensitive probe and ambulatory pH recording system. A pH recording was taken every second.

Time frame:
Day 1 and Day 7 of each treatment period
Reported as:
Mean · percentage of time
Gastric pH >4 Holding Time Ratio (HTR): Percentage of Time Gastric pH Was Above 4 Over a 24-hour Monitoring Period Following Study Drug Administration
percentage of timeVonoprazanLansoprazole
Day 162.40 ± 23.35122.61 ± 17.309
Day 787.81 ± 15.70842.32 ± 25.597
Statistical analysis
  • Vonoprazan vs Lansoprazole · Least-squares mean difference: 38.98 · 95% CI 31.94 to 46.02
  • Vonoprazan vs Lansoprazole · Least-squares mean difference: 44.62 · 95% CI 37.55 to 51.69
PrimaryMean Gastric pH Over a 24-hour Monitoring Period Following Study Drug Administration (pH0-24)

The average gastric pH was a measure of the immediate effect on gastric pH and the duration of effect on gastric pH. Gastric pH was measured continuously over a 24-hour period on Days 1 and 7 of Periods 1 and 2, using a pH and pressure sensitive probe and ambulatory pH recording system. A pH recording was taken every second. The pH scale ranges from 0 to 14 with values below 7 being more acidic and values above 7 being more basic. Normal gastric pH is between 1.5 and 3.5.

Time frame:
Day 1 and Day 7 of each treatment period
Reported as:
Mean · pH
Mean Gastric pH Over a 24-hour Monitoring Period Following Study Drug Administration (pH0-24)
pHVonoprazanLansoprazole
Day 14.606 ± 1.08522.848 ± 0.79923
Day 75.903 ± 0.849003.783 ± 1.2000
Statistical analysis
  • Vonoprazan vs Lansoprazole · Least-squares mean difference: 1.72 · 95% CI 1.40 to 2.04
  • Vonoprazan vs Lansoprazole · Least-squares mean difference: 2.09 · 95% CI 1.74 to 2.44
PrimaryArea Under the Concentration-Time Curve From Time 0 to the 24-Hour Time Point (AUC0-24)

Calculated using the Linear Trapezoidal with Linear Interpolation Method. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

Time frame:
Day 1: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose
Reported as:
Mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time 0 to the 24-Hour Time Point (AUC0-24)
ng*hr/mLVonoprazanLansoprazole
Area Under the Concentration-Time Curve From Time 0 to the 24-Hour Time Point (AUC0-24)200.6 ± 80.9542677 ± 1357.1
PrimaryArea Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)

Calculated as the area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) + (Clast/Kel) where Clast is the last observed/measured concentration and Kel is the apparent first-order terminal elimination rate constant. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

Time frame:
Day 1: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose
Reported as:
Mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)
ng*hr/mLVonoprazanLansoprazole
Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)229.5 ± 98.8412679 ± 1361.0
PrimaryMaximum Observed Plasma Concentration (Cmax)

Cmax was taken directly from bioanalytical data. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

Time frame:
Day 1: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLVonoprazanLansoprazole
Maximum Observed Plasma Concentration (Cmax)21.79 ± 8.32961110 ± 411.88
PrimaryTime to Reach Cmax (Tmax)

Taken from the clinical database as the difference in the time of administration and the time of the blood draw which was associated with the Cmax. If the maximum value occurred at more than one time point, Tmax was defined as the first time point with this value. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

Time frame:
Day 1: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose
Reported as:
Median · hr
Time to Reach Cmax (Tmax)
hrVonoprazanLansoprazole
Time to Reach Cmax (Tmax)2.005 (1.00 to 5.01)1.499 (0.79 to 4.00)
PrimaryArea Under the Concentration-Time Curve During a Dosing Interval (AUCtau) at Steady State (ss)

Calculated using the Linear Trapezoidal with Linear Interpolation Method. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

Time frame:
Day 7: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose
Reported as:
Mean · ng*hr/mL
Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) at Steady State (ss)
ng*hr/mLVonoprazanLansoprazole
Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) at Steady State (ss)261.4 ± 104.183246 ± 2396.4
PrimaryCmax at Steady State (Cmax,ss)

Cmax,ss was taken directly from bioanalytical data. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

Time frame:
Day 7: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose
Reported as:
Mean · ng/mL
Cmax at Steady State (Cmax,ss)
ng/mLVonoprazanLansoprazole
Cmax at Steady State (Cmax,ss)27.39 ± 9.99281164 ± 506.53
PrimaryTmax at Steady State (Tmax,ss)

Taken from the clinical database as the difference in the time of administration and the time of the blood draw which was associated with the Cmax,ss. The analyses of vonoprazan and lansoprazole in plasma samples was performed using validated liquid chromatography-mass spectrometry/mass spectrometry methods.

Time frame:
Day 7: predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 9, 10, 12, 13, 16, and 24 hours postdose
Reported as:
Median · hr
Tmax at Steady State (Tmax,ss)
hrVonoprazanLansoprazole
Tmax at Steady State (Tmax,ss)2.005 (1.53 to 5.00)1.510 (0.75 to 4.02)

Adverse events

Collected over Day 1 to Day 35. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan0/44 (0%)0/44 (0%)9/44 (20.5%)
Lansoprazole0/43 (0%)0/43 (0%)17/43 (39.5%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventVonoprazanLansoprazole
DiarrhoeaGastrointestinal disorders0/444/43
HeadacheNervous system disorders1/444/43
ConstipationGastrointestinal disorders1/443/43
Dry skinSkin and subcutaneous tissue disorders1/442/43
FatigueGeneral disorders2/440/43
ErythemaSkin and subcutaneous tissue disorders2/440/43
PruritusSkin and subcutaneous tissue disorders2/440/43
Abdominal pain lowerGastrointestinal disorders0/441/43
Abdominal pain upperGastrointestinal disorders0/441/43
DyspepsiaGastrointestinal disorders1/441/43

Baseline characteristics

Safety Population - all participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)First Vonoprazan, Then Lansoprazole (Treatment Sequence AB)First Lansoprazole, Then Vonoprazan (Treatment Sequence BA)Total
Mean35.2 ± 8.3037.1 ± 9.9936.1 ± 9.09
Sex: Female, Male
Sex: Female, Male(Participants)First Vonoprazan, Then Lansoprazole (Treatment Sequence AB)First Lansoprazole, Then Vonoprazan (Treatment Sequence BA)Total
Female8412
Male151732
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)First Vonoprazan, Then Lansoprazole (Treatment Sequence AB)First Lansoprazole, Then Vonoprazan (Treatment Sequence BA)Total
Hispanic or Latino12921
Not Hispanic or Latino111223
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)First Vonoprazan, Then Lansoprazole (Treatment Sequence AB)First Lansoprazole, Then Vonoprazan (Treatment Sequence BA)Total
American Indian or Alaska Native011
Asian022
Black or African American325
Native Hawaiian/Pacific Islander011
White171532
White, Asian101
White, Black or African American202
Region of Enrollment
Region of Enrollment(participants)First Vonoprazan, Then Lansoprazole (Treatment Sequence AB)First Lansoprazole, Then Vonoprazan (Treatment Sequence BA)Total
United States232144
08

Study locations

1 site
  • Celerion, 2420 W Baseline Rd,
    Tempe, Arizona 85283, United States
09

References and documents

Publications

  • Laine L, Sharma P, Mulford DJ, Hunt B, Leifke E, Smith N, Howden CW. Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects. Am J Gastroenterol. 2022 Jul 1;117(7):1158-1161. doi: 10.14309/ajg.0000000000001735. Epub 2022 Mar 16. PubMed 35294415 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jun 2021, 4 months.

Results were first posted in Mar 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2021
First posted
Jan 28, 2021
StartActual
Jan 28, 2021
Primary completionActual
Jun 12, 2021
CompletionActual
Jun 26, 2021
Results first posted
Mar 31, 2023
Last update
Mar 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04729101
Lead sponsor
Phathom Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
Jan 28, 2021
Primary completion
Jun 12, 2021
Completion
Jun 26, 2021
Results posted
Mar 31, 2023
Last update
Mar 31, 2023

Study contacts

Medical Director
study director · Phathom Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion